Akston Initiates Clinical Trial of Once-Weekly GLP-1 Weight-Management Therapy for Cats
BEVERLY, Mass., Nov. 25, 2025 /PRNewswire/ — Akston, the Biotech Built for Pets, announced today the start of a clinical study at Cornell University College of Veterinary Medicine to evaluate its once-weekly GLP-1 weight-management therapy for cats. The trial will assess the therapy over a roughly three-month period in client-owned domestic cats affected by excess weight.
Excess weight is one of the most common health issues in cats today. According to the Association for Pet Obesity Prevention (APOP)1, 61% of U.S. cats were classified as overweight or having obesity in 2022, underscoring the scale of the problem and the need for new tools in veterinary care. Awareness of body condition by pet parents appears to be increasing as 33% of U.S. cat parents categorized their cats as overweight or having obesity, compared to 28% in 2023 in the APOP 2024 Pet Weight & Nutrition Opinion Survey. Read More>>